不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
治疗大 B 细胞淋巴瘤的药物获得新批准
英文原题：New Approval for Drug Treating Large B-Cell Lymphoma.
查看英文原题
New Approval for Drug Treating Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
美国食品药品监督管理局已批准lisocabtagene maraleucel（Breyanzi）用于治疗一线治疗后复发/难治性大B细胞淋巴瘤成人患者。由于存在致命或可能致命的细胞因子释放综合征和神经毒性风险，lisocabtagene maraleucel继续在风险评估与缓解策略下处方使用。护士需要在输注该药物后至少七天内密切监测患者是否出现这些及其他严重不良事件。
展开英文摘要原文
The Food and Drug Administration has approved lisocabtagene maraleucel (Breyanzi) to treat large B-cell lymphoma in adults who relapsed or were refractory after first-line treatment.Lisocabtagene maraleucel continues to be prescribed under the Risk Evaluation and Mitigation Strategy due to the risk of fatal or potentially fatal cytokine release syndrome and neurologic toxicities.Nurses need to closely monitor patients for these and for other serious adverse effects for at least seven days after infusion of the drug.
论文信息
- 作者
- Aschenbrenner DS
- 单位
- Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .United States
- 期刊
- The American journal of nursing2022 Oct 1
- 原文标识
- PubMed 36136022 · DOI 10.1097/01.NAJ.0000890212.43727.ab